PHARMACOTHERAPEUTICS FOR NURSE PRACTITIONER PRESCRIBERS This title has been archived.

Author: Anita Wynne, PhD, FNP-C, Teri Woo, RN, MS, CPNP, Ali Olyaei, PharmD, BCPS
Affiliation: University of Portland, OR
Publisher: F.A. Davis Company
Publication Date: 2007
ISBN 10: 080361361X
ISBN 13: 9780803613614
Edition: 2nd

Description:

Now in its second edition, this popular text continues to be the essential resource for the in-depth information that nurse practitioners need to be safe and effective prescribers of medication. The authors focus on applying pharmacologic scientific knowledge to clinical practice by explaining diagnostic and treatment reasoning and rational drug selection, while providing useful clinical pearls from experienced practitioners. Included are: increased coverage of pathophysiology; new chapters on pharmacogenomics, pharmacoeconomics, and pain management.

Table of Contents

Front Matter

  • ABOUT
  • DEDICATION
  • PREFACE
  • ACKNOWLEDGMENTS
  • ABOUT THE AUTHORS
  • CONTRIBUTORS
  • REVIEWERS

UNIT I The Foundation

    CHAPTER 1: THE ROLE OF THE NURSE PRACTITIONER AS PRESCRIBER

    • ROLES OF REGISTERED NURSES AND ADVANCED PRACTICE NURSES WHO ARE NOT NURSE PRACTITIONERS
    • ROLES AND RESPONSIBILITIES OF PHYSICIAN ASSISTANTS
    • ROLES AND RESPONSIBILITIES OF NURSE PRACTITIONERS
    • ADVANCED KNOWLEDGE
    • BENEFITS OF A NURSE PRACTITIONER AS PRESCRIBER
    • CLINICAL JUDGMENT IN PRESCRIBING
    • PRESCRIPTION WRITING
    • OTHER ISSUES TO CONSIDER WHEN WRITING A PRESCRIPTION
    • COLLABORATION WITH OTHER PROVIDERS
    • CURRENT ISSUES AND TRENDS IN HEALTH CARE AND THEIR EFFECT ON PRESCRIPTIVE AUTHORITY
    • REFERENCES

    CHAPTER 2: REVIEW OF BASIC PRINCIPLES OF PHARMACOLOGY

    • PHARMACODYNAMICS
    • PHARMACOKINETICS
    • REFERENCES

    CHAPTER 3: ADVERSE DRUG REACTIONS

    • CATEGORIES OF ADVERSE DRUG REACTIONS
    • CONCLUSION
    • REFERENCE

    CHAPTER 4: PHARMACOGENOMICS

    • GENETICS REVISITED
    • GENETIC DIFFERENCES OF DRUG METABOLISM
    • CYTOCHROME P450
    • P-GLYCOPROTEIN
    • DRUG METABOLISM AND PHARMACOGENOMICS
    • SUMMARY
    • REFERENCES

    CHAPTER 5: PHARMACOECONOMICS

    • PHARMACOECONOMIC STUDIES
    • THE IMPACT OF GENERIC DRUGS ON THE DRUG THERAPY
    • CONCLUSION
    • REFERENCES

    CHAPTER 6: RATIONAL DRUG SELECTION

    • YOUR PERSONAL FORMULARY
    • THE PROCESS OF RATIONAL TREATMENT
    • INDIVIDUALIZING DRUG THERAPY
    • REFERENCES

    CHAPTER 7: LEGAL AND PROFESSIONAL ISSUES IN PRESCRIBING

    • THE PRESCRIPTION
    • FEDERAL DRUG LEGISLATION
    • DRUG-SEEKING BEHAVIOR
    • STATE PRACTICE ACTS
    • THE NEW DRUG APPROVAL PROCESS
    • OFFICIAL LABELING
    • INFORMED CONSENT
    • REFERENCES

    CHAPTER 8: FOSTERING ADHERENCE AND POSITIVE OUTCOMES

    • OVERVIEW OF NONADHERENCE
    • ADVERSE DRUG REACTIONS
    • ASYMPTOMATIC CONDITIONS
    • CHRONIC CONDITIONS
    • KNOWLEDGE DEFICIT AND PATIENT PERCEPTION
    • COGNITIVE IMPAIRMENT AND PSYCHIATRIC ILLNESS
    • CAREGIVER’S ROLES
    • COMPLEXITY OF DRUG REGIMEN AND POLYPHARMACY
    • FINANCIAL IMPACTS
    • COMMUNICATION DIFFICULTIES
    • COMMUNICATION BETWEEN PROVIDERS
    • PATIENT’S RESPONSIBILITIES
    • MEASURING ADHERENCE
    • SUMMARY
    • REFERENCES

    CHAPTER 9: CULTURAL AND ETHNIC INFLUENCES IN PHARMACOTHERAPEUTICS

    • AFRICAN AMERICANS
    • AMERICAN INDIAN–ALASKA NATIVE GROUPS
    • ASIAN AMERICANS/PACIFIC ISLANDERS
    • HISPANICS/MEXICANS
    • NONHISPANIC WHITES
    • SUMMARY
    • REFERENCES

    CHAPTER 10: NUTRITION AND DRUG THERAPY

    • NUTRIENT-DRUG INTERACTIONS
    • NUTRITIONAL SUPPLEMENTATION
    • REFERENCES
    • RESOURCES

    CHAPTER 11: HERBAL THERAPY AND NUTRITIONAL SUPPLEMENTS

    • OVERVIEW OF HERBAL MEDICINE
    • DEFINITIONS
    • HERBAL SAFETY
    • COMMON HERBS USED FOR MEDICINE
    • HERBAL PREPARATIONS
    • CONSIDERATIONS FOR THE ADVANCED PRACTICE NURSE PRESCRIBER
    • REFERENCES

    CHAPTER 12: INFORMATION TECHNOLOGY AND PHARMACOTHERAPEUTICS

    • THE COMPUTER
    • THE INTERNET
    • TELEHEALTH
    • THE FUTURE IN INFORMATION TECHNOLOGY
    • CONCLUSION
    • REFERENCES

    CHAPTER 13: OVER-THE-COUNTER MEDICATIONS

    • NONPRESCRIPTION DRUG USE
    • ANALGESICS AND ANTIPYRETICS
    • ANTIHISTAMINES AND DECONGESTANTS
    • ANTACIDS AND HISTAMINE 2 ANTAGONISTS
    • LAXATIVES
    • ANTIDIARRHEAL PRODUCTS
    • ANTIFUNGAL PREPARATIONS
    • SLEEP AIDS
    • SUMMARY
    • REFERENCES

UNIT II Pharmacotherapeutics with Single Drugs

    CHAPTER 14: DRUGS AFFECTING THE AUTONOMIC NERVOUS SYSTEM

    • ADRENERGIC AGONISTS
    • ALPHA2 AGONISTS: CENTRAL
    • ADRENERGIC ANTAGONISTS
    • ALPHA1 ANTAGONISTS
    • BETA ADRENERGIC ANTAGONISTS (BLOCKERS)
    • COMBINED ALPHA AND BETA ADRENERGIC ANTAGONISTS
    • CHOLINERGIC AGONISTS
    • MUSCARINIC AGONISTS
    • CHOLINESTERASE INHIBITORS
    • NICOTINE
    • CHOLINERGIC BLOCKERS
    • REFERENCES

    CHAPTER 15: DRUGS AFFECTING THE CENTRAL NERVOUS SYSTEM

    • ANOREXIANTS
    • ANTICONVULSANTS
    • ANTIDEPRESSANTS
    • ANTIPSYCHOTICS
    • DOPAMINERGICS
    • ANXIOLYTICS (ANTIANXIETY) AND HYPNOTICS
    • MOOD STABILIZERS
    • OPIOID ANALGESICS AND THEIR ANTAGONISTS
    • STIMULANTS
    • REFERENCES

    CHAPTER 16: DRUGS AFFECTING THE CARDIOVASCULAR AND RENAL SYSTEMS

    • ANGIOTENSIN-CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN II RECEPTOR BLOCKERS
    • CALCIUM CHANNEL BLOCKERS
    • CARDIAC GLYCOSIDES
    • ANTIARRHYTHMICS
    • NITRATES
    • PERIPHERAL VASODILATORS
    • DIURETICS
    • REFERENCES

    CHAPTER 17: DRUGS AFFECTING THE RESPIRATORY SYSTEM

    • BRONCHODILATORS
    • RESPIRATORY INHALANTS
    • COUGH PREPARATIONS
    • REFERENCES

    CHAPTER 18: DRUGS AFFECTING THE HEMATOPOIETIC SYSTEM

    • ANTICOAGULANTS AND ANTIPLATELETS
    • HEMATOPOIETIC GROWTH FACTORS
    • IRON PREPARATIONS
    • FOLIC ACID
    • VITAMIN B12
    • REFERENCES

    CHAPTER 19: DRUGS AFFECTING THE IMMUNE SYSTEM

    • IMMUNIZATIONS
    • ATTENUATED VACCINES
    • INACTIVATED VACCINES
    • IMMUNE GLOBULIN SERUMS
    • DIAGNOSTIC BIOLOGICALS
    • IMMUNOMODULATORS
    • REFERENCES

    CHAPTER 20: DRUGS AFFECTING THE GASTROINTESTINAL SYSTEM

    • ANTACIDS
    • ANTIDIARRHEALS
    • CYTOPROTECTIVE AGENTS
    • ANTIEMETICS
    • EMETICS
    • HISTAMINE2 BLOCKERS
    • PROKINETICS
    • PROTON PUMP INHIBITORS
    • LAXATIVES
    • REFERENCES

    CHAPTER 21: DRUGS AFFECTING THE ENDOCRINE SYSTEM

    • BIOPHOSPHONATES
    • HYPOTHALAMIC AND PITUITARY HORMONES
    • EXOCRINE PANCREATIC ENZYMES
    • ENDOCRINE PANCREATIC HORMONES (INSULIN)
    • ORAL DIABETIC AGENTS
    • SULFONYLUREAS
    • BIGUANIDES
    • ALPHA-GLUCOSIDASE INHIBITORS
    • THIAZOLIDINEDIONES
    • MEGLITINIDES
    • GLUCAGON
    • THYROID AGENTS
    • ANTITHYROID AGENTS
    • REFERENCES

    CHAPTER 22: DRUGS AFFECTING THE REPRODUCTIVE SYSTEM

    • ANDROGENS AND ANTIANDROGENS
    • ESTROGENS AND ANTIESTROGENS
    • PROGESTERONES AND PROGESTERONE ANTAGONISTS
    • OTHER DRUGS AFFECTING THE REPRODUCTIVE SYSTEM
    • REFERENCES

    CHAPTER 23: DRUGS AFFECTING THE INTEGUMENTARY SYSTEM

    • ANTI-INFECTIVES
    • AGENTS USED TO TREAT ACNE
    • TOPICAL CORTICOSTEROIDS
    • TOPICAL IMMUNOMODULATORS
    • TOPICAL ANTIPSORIASIS AGENTS
    • TOPICAL ANTISEBORRHEIC MEDICATIONS
    • TOPICAL ANTIHISTAMINES AND ANTIPRURITICS
    • MOISTURIZERS, EMOLLIENTS, AND LUBRICANTS
    • AGENTS USED IN THE TREATMENT OF BURNS
    • SCABICIDES AND PEDICULICIDES
    • CAUTERIZING AND DESTRUCTIVE AGENTS
    • KERATOLYTICS
    • TOPICAL ANESTHETICS
    • MINOXIDIL
    • MISCELLANEOUS TOPICAL MEDICATIONS
    • REFERENCES

    CHAPTER 24: DRUGS USED IN TREATING INFECTIOUS DISEASES

    • ANTIBIOTICS: BETA-LACTAMS
    • CEPHALOSPORINS
    • FLUOROQUINOLONES
    • LINCOSAMIDES
    • MACROLIDES, AZALIDES, AND KETOLIDES
    • OXALODINONES
    • SULFONAMIDES, TRIMETHOPRIM, AND NITROFURANTOIN
    • TETRACYCLINES
    • VANCOMYCIN
    • ANTIMYCOBACTERIALS
    • ANTIVIRALS
    • NUCLEOSIDE ANALOGUES
    • OTHER ANTIVIRALS FOR INFLUENZA
    • SYSTEMIC AZOLES AND OTHER ANTIFUNGALS
    • ANTHELMINTHICS
    • METRONIDAZOLE AND NITAZOXANIDE
    • REFERENCES

    CHAPTER 25: DRUGS USED IN TREATING INFLAMMATORY PROCESSES

    • ANTIGOUT AND URICOSURIC AGENTS
    • CORTICOSTEROIDS
    • NONSTEROIDAL ANTI- INFLAMMATORY DRUGS
    • ASPIRIN AND NONACETYLATED SALICYLATES
    • REFERENCES

    CHAPTER 26: DRUGS USED IN TREATING EYE AND EAR DISORDERS

    • DRUGS USED IN TREATING EYE DISORDERS
    • DRUGS USED IN TREATING EAR DISORDERS
    • REFERENCES

UNIT III Pharmacotherapeutics With Multiple Drugs

    CHAPTER 27: ANEMIA

    • PATHOPHYSIOLOGY
    • GOALS OF TREATMENT
    • RATIONAL DRUG SELECTION
    • REFERENCES

    CHAPTER 28: CHRONIC STABLE ANGINA AND LOW-RISK UNSTABLE ANGINA

    • PATHOPHYSIOLOGY
    • PHARMACODYNAMICS
    • GOALS OF TREATMENT
    • RATIONAL DRUG SELECTION
    • MONITORING
    • OUTCOME EVALUATION
    • PATIENT EDUCATION
    • REFERENCES

    CHAPTER 29: ANXIETY AND DEPRESSION

    • PATHOPHYSIOLOGY
    • PHARMACODYNAMICS
    • GOALS OF TREATMENT
    • RATIONAL DRUG SELECTION
    • MONITORING
    • OUTCOME EVALUATION
    • PATIENT EDUCATION
    • CONCLUSIONS
    • REFERENCES

    CHAPTER 30: ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE

    • ASTHMA
    • CHRONIC OBSTRUCTIVE PULMONARY DISEASE
    • REFERENCES

    CHAPTER 31: CONTRACEPTION

    • PHYSIOLOGY OF THE NORMAL MENSTRUAL CYCLE
    • PHARMACODYNAMICS
    • GOALS OF TREATMENT
    • RATIONAL DRUG SELECTION
    • MONITORING
    • OUTCOME EVALUATION
    • REFERENCES

    CHAPTER 32: DERMATOLOGIC CONDITIONS

    • DERMATITIS
    • PSORIASIS
    • ACNE AND ACNE ROSACEA
    • SKIN INFECTIONS
    • SKIN INFESTATIONS
    • ALOPECIA ANDROGENETICA (MALE PATTERN BALDNESS)
    • REFERENCES

    CHAPTER 33: DIABETES MELLITUS

    • PATHOPHYSIOLOGY
    • PHARMACODYNAMICS
    • GOALS OF TREATMENT
    • RATIONAL DRUG SELECTION
    • MONITORING
    • OUTCOME EVALUATION
    • PATIENT EDUCATION
    • REFERENCES

    CHAPTER 34: GASTROESOPHAGEAL REFLUX AND PEPTIC ULCER DISEASE

    • GASTROESOPHAGEAL REFLUX DISEASE
    • PEPTIC ULCER DISEASE
    • REFERENCES

    CHAPTER 35: HEADACHES

    • MIGRAINE
    • TENSION-TYPE HEADACHES
    • CHRONIC DAILY HEADACHES
    • CLUSTER HEADACHES
    • DRUG-REBOUND HEADACHES
    • REFERENCES

    CHAPTER 36: HEART FAILURE

    • PATHOPHYSIOLOGY
    • PHARMACODYNAMICS
    • GOALS OF TREATMENT
    • RATIONAL DRUG SELECTION
    • MONITORING
    • OUTCOME EVALUATION
    • PATIENT EDUCATION
    • REFERENCES

    CHAPTER 37: HUMAN IMMUNODEFICIENCY VIRUS DISEASE AND ACQUIRED IMMUNODEFICIENCY SYNDROME

    • PATHOPHYSIOLOGY
    • GOALS OF TREATMENT
    • RATIONAL DRUG SELECTION
    • MONITORING
    • OUTCOME EVALUATION
    • PATIENT EDUCATION
    • REFERENCES

    CHAPTER 38: HORMONE REPLACEMENT THERAPY AND OSTEOPOROSIS

    • HORMONE REPLACEMENT THERAPY
    • OSTEOPOROSIS
    • REFERENCES

    CHAPTER 39: HYPERLIPIDEMIA

    • PATHOPHYSIOLOGY
    • GOALS OF TREATMENT
    • RATIONAL DRUG SELECTION
    • MONITORING
    • OUTCOME EVALUATION
    • PATIENT EDUCATION
    • REFERENCES

    CHAPTER 40: HYPERTENSION

    • PATHOPHYSIOLOGY
    • PHARMACODYNAMICS
    • GOALS OF TREATMENT
    • RATIONAL DRUG SELECTION
    • MONITORING
    • OUTCOME EVALUATION
    • PATIENT EDUCATION
    • REFERENCES

    CHAPTER 41: HYPERTHYROIDISM AND HYPOTHYROIDISM

    • THYROID HORMONE SYNTHESIS
    • THYROID FUNCTION TESTS
    • SCREENING
    • HYPERTHYROIDISM
    • SUBCLINICAL HYPERTHYROIDISM
    • HYPOTHYROIDISM
    • SUBCLINICAL HYPOTHYROIDISM
    • REFERENCES

    CHAPTER 42: PAIN MANAGEMENT: ACUTE AND CHRONIC PAIN

    • OVERVIEW OF PAIN CONCEPTS
    • ACUTE PAIN
    • CHRONIC PAIN
    • REFERENCES

    CHAPTER 43: PNEUMONIA

    • ADULT PATIENTS WITH PNEUMONIA
    • PEDIATRIC PATIENTS WITH PNEUMONIA
    • REFERENCES

    CHAPTER 44: SMOKING CESSATION

    • PATHOPHYSIOLOGY
    • GOALS OF TREATMENT
    • RATIONAL DRUG SELECTION
    • MONITORING
    • OUTCOME EVALUATION
    • PATIENT EDUCATION
    • REFERENCES

    CHAPTER 45: SEXUALLY TRANSMITTED DISEASES AND VAGINITIS

    • SEXUALLY TRANSMITTED DISEASES
    • VAGINITIS
    • REFERENCES

    CHAPTER 46: TUBERCULOSIS

    • PATHOPHYSIOLOGY
    • GOALS OF TREATMENT
    • RATIONAL DRUG SELECTION
    • MONITORING
    • OUTCOME EVALUATION
    • PATIENT EDUCATION
    • PREVENTION OF TUBERCULOSIS
    • REFERENCES

    CHAPTER 47: UPPER RESPIRATORY INFECTIONS, OTITIS MEDIA, AND OTITIS EXTERNA

    • VIRAL UPPER RESPIRATORY INFECTION
    • SINUSITIS
    • OTITIS MEDIA
    • OTITIS EXTERNA
    • REFERENCES

    CHAPTER 48: URINARY TRACT INFECTIONS

    • PATHOPHYSIOLOGY
    • PHARMACODYNAMICS
    • GOALS OF TREATMENT
    • RATIONAL DRUG SELECTION
    • MONITORING
    • OUTCOME EVALUATION
    • PATIENT EDUCATION
    • REFERENCES

UNIT IV Drug Therapy For Special Populations

    CHAPTER 49: WOMEN AS PATIENTS

    • PHARMACOKINETICS AND PHARMACODYNAMICS IN WOMEN
    • FACTORS THAT INFLUENCE MEDICATION ADMINISTRATION
    • FACTORS THAT INFLUENCE POSITIVE OUTCOMES
    • COMMON PROBLEMS THAT REQUIRE MEDICATIONS
    • HEALTH PROMOTION, DISEASE PREVENTION, AND SCREENING
    • GAY AND LESBIAN HEALTH
    • REFERENCES

    CHAPTER 50: PEDIATRIC PATIENTS

    • HISTORICAL PERSPECTIVE ON PEDIATRIC PRESCRIBING
    • PHARMACOKINETIC AND PHARMACODYNAMIC DIFFERENCES IN CHILDREN
    • DEVELOPMENTAL ASPECTS OF PEDIATRIC MEDICATION ADMINISTRATION
    • FACTORS THAT INFLUENCE POSITIVE OUTCOMES
    • REFERENCES

    CHAPTER 51: GERIATRIC PATIENTS

    • GENERAL PRINCIPLES FOR PRESCRIBING FOR OLDER ADULTS
    • PHARMACOKINETICS CHANGES
    • PHARMACODYNAMIC CHANGES
    • PHARMACOTHERAPEUTICS
    • COMMON PHARMACOLOGICAL ISSUES FOR OLDER ADULTS
    • FACTORS INFLUENCING POSITIVE OUTCOMES OR ADHERENCE
    • PHYSICAL CHANGES ASSOCIATED WITH AGING
    • COMMON OTHER PROBLEMS AND CONCERNS
    • REFERENCES

    CHAPTER 52: CHRONIC ILLNESS AND LONG-TERM CARE

    • CHRONIC ILLNESS AND ADHERENCE
    • CHANGES IN THE ADVANCED PRACTICE PRESCRIBER’S ROLE IN CHRONIC ILLNESS
    • CHRONIC ILLNESS AND MEDICATION ADHERENCE: DISEASE-SPECIFIC EXAMPLES
    • MEDICATION ADHERENCE
    • SPECIAL CONSIDERATIONS IN PRESCRIBING FOR PATIENTS IN LONG-TERM CARE FACILITIES
    • REFERENCES

    CHAPTER 53: DRUG THERAPY AT THE END OF LIFE

    • GENERAL PRINCIPLES FOR PRESCRIBING AT THE END OF LIFE
    • PHYSIOLOGICAL CHANGES AND ACCOMPANYING PHARMACOLOGICAL CHANGES AS DEATH APPROACHES
    • COGNITIVE AND PSYCHOLOGICAL CHANGES
    • COMMON SYMPTOMS THAT CAN BE TREATED WITH DRUGS
    • END-OF-LIFE DECISIONS
    • REFERENCES